14.23
+1.01(+7.64%)
Currency In USD
| Previous Close | 13.22 |
| Open | 13.49 |
| Day High | 14.28 |
| Day Low | 13.25 |
| 52-Week High | 27.5 |
| 52-Week Low | 4.81 |
| Volume | 815,831 |
| Average Volume | 1.2M |
| Market Cap | 478.03M |
| PE | -2.28 |
| EPS | -6.23 |
| Moving Average 50 Days | 14.15 |
| Moving Average 200 Days | 11.67 |
| Change | 1.01 |
If you invested $1000 in MBX Biosciences, Inc. Common Stock (MBX) since IPO date, it would be worth $601.69 as of October 21, 2025 at a share price of $14.23. Whereas If you bought $1000 worth of MBX Biosciences, Inc. Common Stock (MBX) shares 1 year ago, it would be worth $601.69 as of October 21, 2025 at a share price of $14.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MBX Biosciences to Participate in November Investor Conferences
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabol
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabo
MBX Biosciences Announces Pricing of Upsized Public Offering
GlobeNewswire Inc.
Sep 25, 2025 1:15 AM GMT
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabo